PDCD1 and esophageal squamous cell carcinoma: The present retrospective case–control study clarified the efficacy of anti‐PD‐1/anti‐PD‐L1 antibody combination with chemotherapy to treat locally advanced ESCC; the pCR rate was 25.8%, identical to the rate achieved with chemoradiotherapy.